Research on stem cells began in the late 19th century in Europe. The term stem cell was coined to describe the fertilized egg that becomes an organism. In the U.S., the adult stem cells were studied in the 1950s. A cancer researcher found large tumors in the scrotums of mice that contained mixtures of differentiated and undifferentiated cells. It concluded that these cells were pluripotent, and they could differentiate into any cells. In 1968, the first successful bone marrow transplant was performed on a child who suffers from an immune deficiency. Subsequently, the methods to derive ESCs from mouse embryos discovered and the method to take stem cells from a human embryo and grow them in a laboratory was developed. Adult and embryonic stem cells, nowadays, are able to treat cancer, Parkinson's disease, baldness, Alzheimer's disease, sclerosis, blindness, Type 1 diabetes, muscle damage and neurological disorders, and many others.
The aim of any stem-cell therapy could lead to cures for a myriad of diseases afflicting humans, and to repair a damaged tissue that can't heal itself. Stem cell therapies not only simply transplanting cells into the body but also be possible to stimulate stem cells already in the body to directing them to grow new, healthy tissue. The isolation of stem and progenitors cells is now being developed for many clinical applications. In Creative Biolabs, the services of disease-specific stem cell therapy development provide various stem cells which correspond to different types of disease.
Disease-specific stem cell therapy is a branch of regenerative medicine that focuses on using stem cells to treat specific diseases or conditions. Stem cells are unique cells in the body that have the ability to differentiate into various types of cells and tissues, making them valuable for repairing and regenerating damaged or diseased tissues.
Researchers are exploring the potential of using disease-specific stem cells to treat a wide range of conditions, including cardiovascular disease, neurodegenerative disorders, autoimmune diseases, and more. While disease-specific stem cell therapy is still in the early stages of development, it holds the promise of offering personalized and targeted treatments for a variety of medical conditions.
Most of the therapeutic mechanism of regenerative medicine action was defined and wide-ranging toxicology studies were done for the stem cells therapy. Also, with the improving of proper standardization and characterization of transplanted cell preparations, the stem cell therapies have demonstrated therapeutic efficacy and benefit in preclinical models through paracrine mechanisms or differentiation. Since target disease will probably influence which of these mechanisms is more important, the stem cells which specific to different diseases are necessary to advance the field. At Creative Biolabs, the disease-specific stem cell therapy development service provide more choices to our customers upon different demands.
Cardiovascular Diseases
Neurodegenerative Diseases
Neurological Diseases
Autoimmune Diseases
Ophthalmological Diseases
Renal Diseases
Liver Diseases
Skin conditions
Degenerative Skeletal Diseases
Please feel free to contact us for more professional consultation.
As a biotechnology company specializing in stem cell research, we offer a comprehensive range of services to support the research and development of novel therapies for various diseases. Our disease-specific stem cell therapy development services include:
Our services are designed to accelerate the development of novel stem cell-based therapies for a wide range of diseases. Please note that our services are for research purposes only and are not intended for diagnosis or treatment.
Below are the findings presented in the article related to disease-specific stem cell therapy development.
Regarding regenerative medicine using iPS cells to treat Parkinson's disease, Jun Takahashi et al. developed a method to efficiently induce dopaminergic neurons from human iPS cells and then sort dopaminergic progenitor cells using the substrate marker CORIN. The transplanted CORIN cells survived well and functioned as midbrain dopaminergic neurons in Parkinson's disease model rats and monkeys with minimal risk of tumor formation. Based on these results, they conducted preclinical studies using clinical-grade iPS cell lines and initiated clinical trials for the treatment of patients with Parkinson's disease.
They used animal models for in vivo studies, and their experimental data showed that human iPS cell-derived DA progenitor cells can function as DA neurons in rodent and monkey PD models without side effects. The clinical trial was initiated to evaluate the safety and efficacy of transplanting human iPS cell-derived DA progenitor cells into the nucleus accumbens of PD patients.
Fig. 1 Clinical trial of iPS cell-based therapy for Parkinson's disease.3
References
For Research Use Only. Not For Clinical Use.
